Clinico-Etiologic Profile of Children and Adolescents with Drug-Resistant Epilepsy in a low-Resource Setting: 10

Dipti Kapoor1, Divyani Garg2, Nitya Beriwal1

  • 1Department of Pediatrics (Neurology Division), Lady Hardinge Medical College and Associated Kalawati Saran Children's Hospital, New Delhi, India.

Insights

Perinatal adverse events and brain infections are the leading causes of drug-resistant epilepsy in children. Preventive measures, including improved perinatal and neonatal care, can reduce this burden.

Area of Science:

  • Pediatric Neurology
  • Epileptology
  • Public Health

Background:

  • Drug-resistant epilepsy affects 25-30% of children with epilepsy.
  • Etiology of epilepsy varies geographically, with limited data from low-resource settings.
  • Understanding regional causes is crucial for targeted interventions.

Purpose of the Study:

  • To describe the clinical and etiologic profile of pediatric drug-resistant epilepsy.
  • To identify region-specific concerns in a low-resource setting.
  • To inform preventive strategies for drug-resistant epilepsy.

Main Methods:

  • Retrospective chart review over 10 years (2011-2020).
  • Inclusion of children aged 1 month to 18 years meeting International League Against Epilepsy (ILAE) criteria for drug-resistant epilepsy.
  • Analysis of clinical data, perinatal history, EEG, MRI, and other evaluations.

Main Results:

  • 593 children enrolled; 52.3% males.
  • Most common seizure type: generalized (76.6%), particularly epileptic spasms (48.1%).
  • Predominant etiologies: perinatal adverse events (e.g., asphyxia 37.9%) and infections; West syndrome (48%) and Lennox-Gastaut syndrome (6.2%) were common electroclinical syndromes.

Conclusions:

  • Perinatal brain injury and infections are primary causes of pediatric drug-resistant epilepsy in this region.
  • Improved perinatal care, institutional deliveries, and optimized neonatal care are vital.
  • Vaccination against meningitis and Japanese B encephalitis can reduce the burden.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
230
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.0K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
223
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
354
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
437
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
453